Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketamine hydrochloride prolonged-release
- Development stage
- Unknown
- Lead developer
- University of Southern California
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
160mg/day Ketamine HCl Prolonged Release is an investigational oral tablet formulation of ketamine hydrochloride, a small molecule N-methyl-D-aspartate (NMDA) receptor antagonist. Developed by the University of Southern California, this prolonged-release formulation is designed to provide sustained therapeutic levels of ketamine while minimizing the peak-dose side effects typically associated with immediate-release formulations. It is being evaluated in a Phase 2 clinical trial for the treatment of chronic pain associated with Complex Regional Pain Syndrome (CRPS). By blocking NMDA receptors, the drug aims to reduce central sensitization and wind-up pain phenomena, which are key pathophysiological mechanisms in CRPS.
- Other names
- 160mg Ketamine PR160mg/day Ketamine HCl Prolonged ReleaseKetamine HCl PRKetamine HCl Prolonged Releaseextended-release ketamine hydrochlorideketamine hydrochloride extended-releaseketamine hydrochloride prolonged-release
02
Targets
MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on ketamine hydrochloride prolonged-release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketamine hydrochloride prolonged-release.